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radiotherapy < 0.2 ng/mL. Salvage RT was defined as radiation 
delayed until PSA rose above a threshold (≥ 0.2ng/mL). All 
patients were followed for three years. 
Results: Forty-nine patients (pre-GUROC: n = 20, post-GUROC: n 
= 29) met the inclusion criteria. Age, clinical, and pathological 
factors were similar between the two cohorts, including rates of 
ECE, SVI and post RP PSA (p > 0.05), however, there were more 
patients with positive margins in the post-GUROC cohort (50% 
versus 79%, p = 0.03). Rate of aRT offered was not significantly 
different between the pre- versus post-GUROC cohort, 65% 
versus 69%, (p > 0.05). Furthermore, no differences were noted 
between the rate of salvage RT or no RT offered between the 
cohorts: 15% versus 10% (p > 0.05), and 20% versus 21% (p > 0.05), 
respectively. 
Conclusions: Two-thirds of eligible prostate cancer patients 
referred to radiation oncologists in a particular Canadian 
province were offered aRT. This practice pattern did not 
significantly change after the publication of the GUROC 
recommendations. 
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Purpose: The standard treatment for men with newly diagnosed 
metastatic prostate cancer (mPCa) is androgen deprivation 
therapy (ADT). Local radiotherapy (RT) to the prostate has 
traditionally been reserved for men who require symptomatic 
relief in patients with metastatic disease. However, local RT may 
have other benefits in addition to symptomatic relief. This study 
investigates the impact of local RT on overall survival (OS) in men 
with newly diagnosed mPCa. 
Methods and Materials: This is a retrospective, population-based 
study of patients age > = 18 years diagnosed with metastatic (M1) 
prostate cancer in Manitoba between 2004-2013. Patients with 
neuroendocrine or small cell histology were excluded. Data was 
collected from Cancer Registry and electronic charts including 
age, T/N/M stage, PSA, Charlson comorbidity score, RT, surgery, 
systemic therapy, Gleason score, and ECOG performance status. 
Cox regression was used to predict OS. Likelihood ratio testing 
was used to identify factors associated with OS. A p value < 0.05 
was considered significant. 
Results: A total of 323 patients were included and 25 (7.7%) 
received RT to the prostate within one year of diagnosis. The 
median follow up was 2.21 years. The mean age was 71.9 years. 
Clinical T stage included T1 (9.3%), T2 (26.6%), T3 (21.7%) and 
T4 (10.5%) and TX (31.9%), N stage ranged from N0 (21.4%), N1 
(37.5%), NX (41.2%). M stages consisted of M1a/M1b (63.5%), M1c 
(14.2%) or MX (22.3%). Of the 25 patients who received prostate 
RT, 15 received high dose (≥ 50 Gy) and 10 low dose (< 50 Gy). 
Multivariable analysis showed a hazard ratio (HR) for death of 
1.09 (95% CI 0.64-1.85, p = 0.75) for patients receiving prostate 
RT (any dose) compared to those without prostate RT. 
Furthermore, the HR for high dose RT was 0.73 (95% CI 0.35-1.53, 
p = 0.41) and 1.77 (95% CI 0.89-3.52, p = 0.1) for low dose RT. 
Conclusions: In this cohort of patients with newly diagnosed 
mPCa, there was no association between RT to the prostate and 
OS. However, this study was limited by statistical power and 
additional investigation in a larger population is needed. 
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Purpose:  Dose escalation (DE) increases biochemical and local 
control in PCa. Addition of image guidance improves outcomes 
of highly conformal techniques. However, the benefit of DE and 
optimal fractionation in the context of IGRT remains unknown. 
Herein, we determine biochemical outcomes in three patient 
cohorts treated with progressively DE schemes and daily 
image-guidance (IG). 
Methods and Materials: We analyzed prospectively collected 
data from a single Institution. Departmental standard included 
three sequential prostate-only schedules, A: 75.6 Gy (1.8 Gy/d); 
B: 79.8 Gy (1.9 Gy/d); C: 78 Gy (2 Gy/d). Daily IG consisted of 
fiducial markers and daily orthogonal imaging (predominantly A 
and B) or cone beam CT (mainly C). Patients were categorized 
into NCCN risk categories, and intermediate-risk (IR) subdivided 
into favourable and unfavourable (Zumsteg’s criteria). 
Primary endpoint was biochemical recurrence (BCR) by Phoenix 
definition (PSA nadir + 2 ng/ml). Biochemical relapse-free 
rates (bRFR) were compared between three dose schedules 
and risk groups using Cox proportional hazard models and 
Kaplan-Meier method.
Results: Nine hundred and eighty-seven patients were included 
with a median age of 71.7 years. Risk category distribution was 
18% (low), 68% (IR) and 13% (high). Of IR patients (673), 62% were 
unfavourable. Two hundred and ninety-three (30%), 315 (32%) 
and 379 (38%) patients were treated with A, B and C, 
respectively. Overall, 11% of patients received ADT. Age, initial 
PSA, T-stage, Gleason score, use of ADT and risk 
category distribution were not different between three 
groups. Median follow up was 5.9 years (0.1-16.5): 9.0 years 
(0.1-16.5), 9.6 years (0.1-14.3) and 4.9 years (0.2-9.5) for A, 
B and C. bRFR was significantly different between A, B and C 
(p < 0.0001) with five year rates of 76%, 82%, 91% and eight 
year rates of 54%, 64% and 80%, respectively. Overall, 
compared to C, those treated with A and B had a HR of 2.67 
(95% CI 1.87-3.81, p < 0.001) and 1.93 (95% CI 1.34-2.77, p < 
0.001) for BCR, respectively. In low-risk category, group A 
had a higher risk of BCR compared to C (HR 4.1, 95% CI 
1.18-14.32, p = 0.027), but no difference between B and C was 
observed (p = 0.17). For favourable IR, A and B had increased 
risk of BCR (HR 4.38, 95% CI 1.68-11.4, p = 0.0025 and HR 3.05, 
95% CI 1.18-7.9, p = 0.022, respectively) compared to C. 
Findings were similar for unfavourable IR group (HR 2.24, 95% CI 
1.36-3.67, p = 0.0015 and HR 1.88, 95% CI 1.13-3.14, p = 0.015 
for A and B versus C, respectively). In high-risk category, no 
differences in BCR rates were observed.  
Conclusions:  We observed a possible continuous dose response 
and bRFR improvement with progressive DE in the context of 
daily IG, particularly significant for IR categories. With long-term 
follow up, we observed a continuous occurrence of BCR. Given 
the limitations of retrospective studies, our results justify 
further dosimetric- and technique-related factors analyses. 
Prospective validation of these findings and consideration for 
higher DE-IGRT seem warranted to improve outcomes for PCa. 
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